Skip to main content
. Author manuscript; available in PMC: 2022 Feb 7.
Published in final edited form as: Clin Cancer Res. 2017 Oct 27;24(2):395–406. doi: 10.1158/1078-0432.CCR-17-1983

Figure 2. In vivo efficacy examination of trastuzumab on HR+/HER2+ PDXs.

Figure 2.

Four-week treatment of trastuzumab (10 mg/kg/twice intraperitoneal injection per week; TRA) or sterile saline (CTRL) was performed on the intact mice bearing COH-SC1 (n=7) or E2-supplemented COH-SC31 (n=5) tumors. Tumor volume (A) and tumor weight (B) were monitored and summarized as Mean±SEM with two-way ANOVA analysis for p value. See also Supplementary Figure 3A for body weight observations.